Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Blood (2024) 143 (2): 178–182.

https://doi.org/10.1182/blood.2023022345

Published: 2024

Includes: Supplemental data

Journal Articles

Loss of endothelial membrane KIT ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells

Sahoko Matsuoka, Raffaella Facchini, Tiago C. Luis, Joana Carrelha, Petter S. Woll, Takuo Mizukami, Bishan Wu, Hanane Boukarabila, Mario Buono, Ruggiero Norfo, Fumio Arai, Toshio Suda, Adam J. Mead, Claus Nerlov, Sten Eirik W. Jacobsen

Blood (2023) 142 (19): 1622–1632.

https://doi.org/10.1182/blood.2022019018

Published: 2023

Includes: Supplemental data

Journal Articles

Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A

Blood (2023) 142 (Supplement 1): 993.

https://doi.org/10.1182/blood-2023-178556

Published: 2023

Journal Articles

A Multiomic Single-Cell Atlas of Human Myelopoiesis Reveals Cellular and Molecular Drivers of Immunomodulatory Drug-Induced Neutropenia

Christina Simoglou Karali, Simone Riva, Sally-Ann Clark, Sean Wen, Nikolaos Sousos, Eleni Louka, E. Ravza Gür, Nawshad Hayder, William E. Pierceall, Anjan Thakurta, Anita K. Gandhi, Patrick R Hagner, Jim Hughes, Adam J Mead

Blood (2023) 142 (Supplement 1): 935.

https://doi.org/10.1182/blood-2023-182041

Published: 2023

Journal Articles

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Blood (2023) 142 (Supplement 1): 620.

https://doi.org/10.1182/blood-2023-173509

Published: 2023

Journal Articles

Platelets Sequester Extracellular DNA, Capturing Tumour-Derived and Free Fetal DNA

Blood (2023) 142 (Supplement 1): 277.

https://doi.org/10.1182/blood-2023-182697

Published: 2023

Journal Articles

Platelet-Restricted Clonal Hematopoiesis

Nikolaos Sousos, Lauren Murphy, Sean Wen, Angela Hamblin, Sally-Ann Clark, Christina Simoglou Karali, Jessica Whittle, Zemin Ren, Haseeb Rahman, Nawshad Hayder, Akriti Rastogi, Michael Jacobs, Susan Shapiro, Bethan Psaila, Adam J Mead

Blood (2023) 142 (Supplement 1): 814.

https://doi.org/10.1182/blood-2023-188000

Published: 2023

Journal Articles

The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups

Jennifer O Sullivan, Amy Wood, Sean Wen, Angela Hamblin, Sonia Fox, Christina Yap, Mary Frances McMullin, Nicholas C. P. Cross, Claire N Harrison, Adam J Mead

Blood (2023) 142 (Supplement 1): 4552.

https://doi.org/10.1182/blood-2023-185043

Published: 2023

Journal Articles

Cooperation between SF3B1 and JAK2 V617F Mutations Accelerates Fibrotic Progression in Myeloproliferative Neoplasms By Enhancing STAT1 Signaling

Jennifer O Sullivan, Sean Wen, Affaf Aliouat, Alba Rodriguez-Meira, Sally-Ann Clark, Neil Ashley, Amy Wood, Ramy Slama, Guanlin Wang, Angela Hamblin, Lauren Murphy, Christina Simoglou Karali, Charlotte K Brierley, Adam P Cribbs, Aimee Paterson, Claire N Harrison, Bethan Psaila, Adam J Mead

Blood (2023) 142 (Supplement 1): 861.

https://doi.org/10.1182/blood-2023-185118

Published: 2023

Journal Articles

Single-Cell Mutation Profiling and Alternative Splicing Analysis Reveals Distinct Aberrant Splicing of U2AF1 S34 and U2AF1 Q157 in Myeloid Malignancies

Sean Wen, Jennifer O Sullivan, Joanna Baxter, Nikolaos Sousos, Adam J Mead, Alba Rodriguez-Meira

Blood (2023) 142 (Supplement 1): 4133.

https://doi.org/10.1182/blood-2023-185999

Published: 2023

Journal Articles

Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone

Adam J Mead, Claire N Harrison, Brian Huntly, Bethan Psaila, Rebecca Boucher, Sonia Fox, Louise Hopkins, Joseph Rogers, Charlotte Gaskell, Amit Patel

Blood (2023) 142 (Supplement 1): 6442.

https://doi.org/10.1182/blood-2023-185798

Published: 2023

Journal Articles

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy

Blood (2023) 141 (11): 1316–1321.

https://doi.org/10.1182/blood.2022018602

Published: 2023

Includes: Supplemental data

Journal Articles

Single-cell methods in myeloproliferative neoplasms: old questions, new technologies

Jennifer Mary O’Sullivan, Adam J. Mead, Bethan Psaila

Blood (2023) 141 (4): 380–390.

https://doi.org/10.1182/blood.2021014668

Published: 2023

Journal Articles

Cross-Talk between Hematopoietic Cells and Fibroblast Subsets Drives Inflammation and Remodelling of the Bone Marrow Microenvironment in Myeloproliferative Neoplasms

Blood (2022) 140 (Supplement 1): 1091–1092.

https://doi.org/10.1182/blood-2022-165493

Published: 2022

Journal Articles

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Blood (2022) 140 (Supplement 1): 9677–9680.

https://doi.org/10.1182/blood-2022-162547

Published: 2022

Journal Articles

Quantitative MRI Detects Multi-Organ Impairment in Patients with Chronic Myeloid Neoplasms

Oni Chowdhury, Sophie Reed, Alison Telford, Adriana Roca-Fernandez, Samiya Mahmood, Soubera Rymell, Michael Smith, Antonella Sultana, Nicole Eichert, Michele Pansini, Helena Thomaides-Brears, Bethan Psaila, Adam J Mead

Blood (2022) 140 (Supplement 1): 9706–9708.

https://doi.org/10.1182/blood-2022-165964

Published: 2022

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Blood (2022) 140 (Supplement 1): 1784–1787.

https://doi.org/10.1182/blood-2022-159047

Published: 2022

Journal Articles

Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Blood (2022) 140 (Supplement 1): 1781–1783.

https://doi.org/10.1182/blood-2022-157273

Published: 2022

Journal Articles

Single-Cell Transcriptome Analysis Reveals Pathways That Drive Dyserythropoiesis in Myelodysplastic Syndromes, Which Are Targeted By Luspatercept

Onima Chowdhury, Douglas RA Silveira, Sophie Reed, Jennifer O'Sullivan, Sally-Ann Clark, Neil Ashley, Bethan Psaila, Supat Thongjuea, Adam J Mead, Lynn Quek

Blood (2022) 140 (Supplement 1): 9753–9754.

https://doi.org/10.1182/blood-2022-165865

Published: 2022

Journal Articles

Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment

Blood (2022) 140 (Supplement 1): 9751–9752.

https://doi.org/10.1182/blood-2022-163158

Published: 2022

NARROW

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Loss of endothelial membrane KIT ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells

Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A

A Multiomic Single-Cell Atlas of Human Myelopoiesis Reveals Cellular and Molecular Drivers of Immunomodulatory Drug-Induced Neutropenia

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Platelets Sequester Extracellular DNA, Capturing Tumour-Derived and Free Fetal DNA

Platelet-Restricted Clonal Hematopoiesis

The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups

Cooperation between SF3B1 and JAK2 V617F Mutations Accelerates Fibrotic Progression in Myeloproliferative Neoplasms By Enhancing STAT1 Signaling

Single-Cell Mutation Profiling and Alternative Splicing Analysis Reveals Distinct Aberrant Splicing of U2AF1 S34 and U2AF1 Q157 in Myeloid Malignancies

Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy

Single-cell methods in myeloproliferative neoplasms: old questions, new technologies

Cross-Talk between Hematopoietic Cells and Fibroblast Subsets Drives Inflammation and Remodelling of the Bone Marrow Microenvironment in Myeloproliferative Neoplasms

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Quantitative MRI Detects Multi-Organ Impairment in Patients with Chronic Myeloid Neoplasms

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Single-Cell Transcriptome Analysis Reveals Pathways That Drive Dyserythropoiesis in Myelodysplastic Syndromes, Which Are Targeted By Luspatercept

Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only